2.6 times growth in revenues and leveraging fixed costs ᅠ.

2.6 times growth in revenues and leveraging fixed costs ᅠ.

The distribution of the medicines in the spring of 930 and in the summer produced a net profit of 1,346 billion tomans; A total of about 2.3 MET in 6 months, which is about 3.5 times of the same period and is more than the total profit of 1404 (1.6 MET). The income for 6 months reached about 48 Hamats with a growth of 159%. The gross profit rate, as always in a broadcasting company, remains constant around 10%. The main part of the report is in the costs: management and distribution costs only increased by 49%, while revenues increased more than 2.5 times. For this reason, the operating profit rate increased from 5% to 7% and the operating profit increased 3.5 times. The financial cost also tripled and reached about 500 billion tomans, but this is not a large number compared to the increase in income. The stock market is about 24 stocks and its P/E is 7.6, which is lower than the pharmaceutical group's P/E (10.9). The share's return since the opening of the market was 273%, which is more than twice the total of the index (120%).

ᅠ Value investment.

ᅠ.